FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to a method for increasing cytotoxicity of non-activated macrophages of phenotype M0, differentiated from mouse bone marrow cells. Method involves using M-CSF at concentration of 20 ng/ml with respect to tumour cells by Alprostadil exposure and is characterized by the fact that macrophages are cultured for 24 hours in the presence of Alprostadil at concentration of 10 mcmol.
EFFECT: invention is effective in Alprostadil-mediated increase in cytotoxicity of macrophages with respect to tumour cells.
1 cl, 5 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF GRAPHENE OXIDE TO ACTIVATE PHAGOCYTIC FUNCTION OF MACROPHAGES | 2022 |
|
RU2809372C1 |
| METHOD FOR TUMOUR GROWTH INHIBITION IN EXPERIMENT | 2015 |
|
RU2599438C1 |
| METHOD OF TUMOUR GROWTH INHIBITION BASED ON IN VITRO REPROGRAMMING MACROPHAGES ON M1 PHENOTYPE WITH HIGH ABILITY OF NITRIC OXIDE PRODUCTION IN EXPERIMENT | 2015 |
|
RU2599545C1 |
| METHOD OF SELECTING MEDICINAL PRODUCTS FOR PHARMACOLOGICAL INDUCTION OF MITOCHONDRIAL DYSFUNCTION IN MACROPHAGES FOR ANTITUMOR THERAPY | 2023 |
|
RU2810558C1 |
| MODIFIED MONOCYTES/MACROPHAGES EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2766690C2 |
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| METHOD FOR ENHANCING ANTITUMOR T-CELL IMMUNITY IN LUNG CANCER PATIENTS | 2022 |
|
RU2793914C1 |
| COMBINED CELL TRANSPLANT BASED ON LYMPHOKINE-ACTIVATED KILLERS AND DENDRITE CELLS, METHOD FOR PRODUCTION THEREOF AND METHOD FOR TREATMENT AND PROPHYLAXIS OF MALIGNANT, INFECTIVE DISEASES AND IMMUNODEFICIENT CONDITIONS | 2006 |
|
RU2309753C1 |
| MATERIALS AND METHODS FOR CANCER TREATMENT | 2019 |
|
RU2787828C2 |
| BIOMEDICAL CELL PRODUCT WITH ANTI-HER2 SPECIFIC ANTI-TUMOUR ACTIVITY | 2019 |
|
RU2728361C1 |
